Children's Health in London and Luton (CHILL)

Child Development Clinical Trial

— CHILL  

Official title:

Investigating the Impact of London's Ultra Low Emission Zone on Children's Respiratory Health

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04695093
• Other study ID #: 239719
• Status: Active, not recruiting
• Start date: March 28, 2018
• Est. completion date: December 31, 2023

Study information

• Verified date: September 2020
• Source: Queen Mary University of London
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Investigating the impact of London's Ultra Low Emission Zone on children's respiratory health

Description:

Strong evidence links urban air pollution to restrictions in children's lung growth and development and other adverse effects, including increases in respiratory and allergy symptoms, respiratory infections, asthma, and health care use. Effective interventions are urgently needed that reduce air pollution and improve child health. Low Emission Zones (LEZ) are becoming widespread but are expensive to implement and of unproven health benefit. London has some of the worst air pollution in Europe. London's Ultra Low Emission Zone (ULEZ) is the central component of London's air quality strategy. Its implementation provides a unique opportunity to test the impact of a city-wide LEZ on children's health. The intervention: The ULEZ is an area within which all vehicles must meet exhaust emission standards or pay a daily charge to travel. It will be implemented and paid for by Transport for London. Starting in 2019, the ULEZ will initially cover London's central Congestion Charging Zone, an area bounded by the London Inner Ring Road, that includes the City of London plus adjacent areas of eight radially adjoining Boroughs. It is projected to deliver for central London by 2020 emission reductions of -49% for NOx; - 47% for NO2; and -11% for PM10. Subject to consultation, the ULEZ will subsequently extend to include an inner London area (within London's North and South Circular roads), and a London-wide area, for heavy vehicles only. Questions: 1. What is the impact of the ULEZ on children's lung growth (the primary outcome)? 2. What is the impact of the ULEZ on secondary outcomes, including self-reported symptoms, respiratory infection, health care use and costs? 3. Does the ULEZ reduce health inequalities? 4) Is the ULEZ good value for money? Study design: Quasi-experimental study using a parallel cohort design. Population: 1520 children aged 6-9 yrs old, recruited in 26 London primary schools (school years 2, 3 and 4) in London's Central Ultra Low Emission Zone. Intervention: Ultra Low Emission Zone Comparison: 1520 children aged 6-9 yrs old, recruited in 26 primary schools (school years 2, 3 and 4) in Luton, matched for ethnicity, deprivation and baseline air quality. Outcome: PRIMARY: Lung function growth (post-bronchodilator forced expiratory volume in one second (FEV1) measured by high quality spirometry at sequential annual school visits over four years. SECONDARY: Forced vital capacity (FVC), exhaled nitric oxide (FeNO), quality of life, respiratory infections, health care use, health costs. Sample size: To detect a 15ml/year FEV1 difference between central and outer London cohorts at 90% power and 0.05 significance requires children in each cohort, inflated to allow for clustering effect of schools, spirometry success, child and school attrition, and pre-specified sub group analyses, giving a total of 3120 children (60 children from 26 schools in each cohort). Duration: 6 years Air quality data: Modeled exposures by London Air Quality Network Data management: NIHR accredited Pragmatic Clinical Trials Unit Analysis: Interaction analysis controlling for effect modifiers (eg passive smoke; ethnicity); health economic cost consequence analysis.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3312
• Est. completion date: December 31, 2023
• Est. primary completion date: March 28, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 9 Years to 9 Years

Eligibility

Inclusion Criteria:

• Inclusion criteria for schools:
• Primary schools within, or with catchment areas that include, the Central London ULEZ.
• Primary schools within the Borough of Luton and town of Dunstable.
• State or independent sectors.

Inclusion criteria for children:

• Children attending a study school, in years 2, 3, or 4, at study inception.

Exclusion Criteria:

• Exclusion criteria for schools:
• Schools that are not primary schools within the above boundaries.

Exclusion criteria for children:

• Children with learning or physical disabilities sufficient for them to be unable to give informed assent to the study, or to carry out study procedures.
• Children with major lung disease (not including asthma).

Related Conditions & MeSH terms

• Child Development
• Pollution; Exposure
• Respiration Disorders
• Respiratory Disease
• Respiratory Tract Diseases

Intervention

Other:
• Ultra Low Emission Zone (ULEZ)
The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles. The ULEZ will subsequently be extended to include: In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily. In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area.

Locations

Country	Name	City	State
United Kingdom	Queen Mary University of London	London

Sponsors (6)

Lead Sponsor	Collaborator
Queen Mary University of London	King's College London, University of Bedfordshire, University of Cambridge, University of Edinburgh, University of Southern California

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lung function growth as change in forced expiratory volume in one second (FEV1) per year	Measured by annual spirometry, as annual change in FEV1/year over 4 years	Four years, 2018 -2021
Secondary	Air quality, nitrogen dioxide (NO2) concentration derived from the the KCLUrban dispersion model	Annual nitrogen dioxide (NO2) concentration (micrograms/cubic meter NO2)	Four years, 2018 -2021
Secondary	Air quality, oxides of nitrogen (NOx) concentration derived from the KCLUrban dispersion model	Annual oxides of nitrogen (NOx) concentration (micrograms/cubic meter NOx)	Four years, 2018 -2021
Secondary	Air quality, particulate matter diameter <2.5microns derived from the KCLUrban dispersion model	Annual particulate matter diameter <2.5microns (PM2.5) concentration (micrograms/cubic meter PM2.5)	Four years, 2018 -2021
Secondary	Air quality, particulate matter diameter <2.5microns derived from the KCLUrban dispersion model	Annual particulate matter diameter <2.5microns (PM2.5) concentration (micrograms/cubic meter PM10)	Four years, 2018 -2021
Secondary	Lung capacity as FVC (forced vital capacity)	Measured by annual spirometry, as FVC in litres	Four years, 2018 -2021
Secondary	Annual prevalence of wheeze, as proportion (%) of respondents reporting wheeze	International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire for 6-7 year olds	Four years, 2018 -2021
Secondary	Annual prevalence of eczema, as proportion (%) of respondents reporting eczema	International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire for 6-7 year olds	Four years, 2018 -2021
Secondary	Annual prevalence of rhinitis, as proportion (%) of respondents reporting rhinitis	International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire for 6-7 year olds	Four years, 2018 -2021
Secondary	Annual prevalence/participant of upper respiratory tract infections	Electronic download of coded NHS health record data	Four years, 2018 -2021
Secondary	Annual prevalence/participant of lower respiratory tract infections	Electronic download of coded NHS health record data	Four years, 2018 -2021
Secondary	Physical activity, as Percentage time in Moderate to Vigorous Physical activity per participant (MVPA)	Annual hip accelerometer records of participants, measured over one week	Four years, 2018 -2021
Secondary	Annual health care use per participant	Electronic download of coded NHS health record data	Four years, 2018 -2021
Secondary	Annual health care costs per participant	Electronic download of coded NHS health record data and self report data	Four years, 2018 -2021
Secondary	Cognitive function as average Movement Time in seconds (MT) on the Clinical Kinematic Assessment Test	Annual Clinical Kinematic Assessment Test	Three years, 2019 -2021
Secondary	Child Quality of Life as score out of 40	Annual parental completion of the CHU9D (Child Health Utility 9 Dimension) questionnaire	Four years, 2018 -2021